Skip to main content
Premium Trial:

Request an Annual Quote

Isis and Genelabs Collaborate on Efforts For Biological Defense

Premium

REDWOOD CITY, Calif.--Isis Pharmaceuticals and Genelabs Technologies, both with research grants from the Defense Advanced Research Projects Agency, which encourages drug development to combat pathogens used in biological warfare, entered into a collaborative agreement recently. Because the two companies share an interest in understanding how nucleic acids can be exploited as drug targets, the collaborative effort has the potential to significantly advance both firms' research objectives, they said.

The companies will collaborate to understand the basic properties of molecules needed to bind nucleic acids and will use the information in their respective drug discovery programs. Isis will provide chemical libraries of novel small-molecule compounds to Genelabs to test in its assays for binding DNA. Genelabs will screen these compounds in its proprietary DNA-binding assay, Merlin. Isis's drug discovery program will focus on RNA, while the Genelabs program will focus on DNA.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.